Eleven Biotherapeutics Inc. (NASDAQ:EBIO) major shareholder Ventures Fund 2007 L. Flagship sold 443,422 shares of the stock in a transaction that occurred on Friday, September 23rd. The shares were sold at an average price of $3.16, for a total value of $1,401,213.52. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Eleven Biotherapeutics Inc. (NASDAQ:EBIO) opened at 2.98 on Thursday. The company’s 50-day moving average price is $4.30 and its 200-day moving average price is $2.29. Eleven Biotherapeutics Inc. has a 52 week low of $0.25 and a 52 week high of $5.97. The company’s market capitalization is $45.87 million.
Eleven Biotherapeutics (NASDAQ:EBIO) last announced its earnings results on Friday, August 12th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter. Eleven Biotherapeutics had a negative net margin of 2,995.34% and a negative return on equity of 207.40%. Equities analysts forecast that Eleven Biotherapeutics Inc. will post ($1.75) earnings per share for the current fiscal year.
A number of hedge funds have recently made changes to their positions in the stock. Flagship Ventures Fund 2007 L.P. purchased a new stake in shares of Eleven Biotherapeutics during the first quarter worth about $610,000. Flagship Ventures Fund IV L.P. purchased a new stake in shares of Eleven Biotherapeutics during the first quarter worth about $469,000. Flagship Ventures Fund IV General Partner LLC purchased a new stake in shares of Eleven Biotherapeutics during the second quarter worth about $2,464,000. Sabby Management LLC raised its stake in shares of Eleven Biotherapeutics by 525.6% in the first quarter. Sabby Management LLC now owns 1,213,984 shares of the biopharmaceutical company’s stock worth $387,000 after buying an additional 1,019,943 shares during the last quarter. Finally, Boxer Capital LLC purchased a new stake in shares of Eleven Biotherapeutics during the second quarter worth about $1,670,000. 34.32% of the stock is currently owned by institutional investors.
About Eleven Biotherapeutics
Eleven Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company through AMP-Rx, a protein engineering platform, is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. The Company designs, engineers and generates a pipeline of protein therapeutic candidates that target cytokines, which are central to diseases of the eye.
Receive News & Ratings for Eleven Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.